Krystal Biotech

1 active phase 3 trial and 4 active phase 2 trials led by this company, mostly in wrinkles in decolletage, dystrophic epidermolysis bullosa, neurotrophic keratitis. The ones with the nearest registered primary completion date still ahead:

• Dec 2026A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaPhase 3RecruitingDystrophic Epidermolysis Bullosa
• Dec 2026A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic KeratitisPhase 2RecruitingNeurotrophic Keratitis
• Feb 2027A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsPhase 2RecruitingLung Cancer, Non-small Cell
• Jul 2027A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid TumorsPhase 2RecruitingCancer

1 trial has a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.